# LDHC Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- The LDHC gene encodes a testis-specific lactate dehydrogenase isozyme (LDH-C₄) crucial for spermatogenesis and sperm motility, catalyzing pyruvate to lactate conversion. Its expression is tightly regulated by the FSH → cAMP → PKA → CREMτ axis and involves active promoter demethylation in the testis.
- LDHC's unique 7-amino acid insertion in the substrate specificity loop confers distinct kinetic properties and allows interaction with glycolytic metabolons and sperm structural proteins like AKAP4, essential for flagellar function and local ATP supply.
- Germline mutations in LDHC, such as p.Arg96Trp and p.Arg193His, are causative of male infertility, leading to azoospermia or severe oligospermia due to impaired catalytic activity or cofactor binding. Somatic mutations in LDHC, particularly gain-of-function variants like p.Gly32Asp, are observed in testicular germ cell tumors and non-small cell lung cancer, promoting the Warburg effect and chemoresistance.
- LDHC is a validated drug target for non-hormonal male contraceptives and cancer therapy. Small-molecule inhibitors like oxamide derivatives and isoxazolines demonstrate potent and selective inhibition of LDHC, with some showing promise in preclinical studies for cancer treatment and male contraception via antisense oligonucleotides.
---
## Executive Summary & Key Metadata
The **LDHC** gene encodes L-lactate dehydrogenase C (LDH-C₄), a testis-specific isozyme of the lactate dehydrogenase (LDH) family. This enzyme catalyzes the reversible interconversion of pyruvate and L-lactate, coupled with the redox conversion of NADH to NAD⁺. Unlike the somatic isoforms LDHA and LDHB, LDHC is expressed exclusively in the male germline, specifically in spermatocytes and spermatids, where it is essential for spermatogenesis and sperm motility. Beyond its canonical metabolic role, LDHC has emerged as a critical oncofetal antigen and a high-value therapeutic target in male cancers, particularly testicular germ cell tumors and lung cancer. The gene is also a paradigm for tissue-specific gene regulation, exhibiting a tightly controlled, developmentally programmed expression pattern.
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | LDHC |
| **UniProt Accession** | P07864 |
| **Representative PDB ID** | 6J4G (crystal structure of human LDH-C₄ in complex with NADH and inhibitor) |
| **Chromosomal Locus** | 11p15.1 (GRCh38: chr11:18,412,432–18,431,329, minus strand) |
| **Primary Molecular Function** | Catalysis of pyruvate ↔ L-lactate interconversion; NAD⁺/NADH oxidoreductase activity |
| **Tissue Specificity** | Testis (pachytene spermatocytes, round spermatids); ectopic expression in multiple cancers |
| **Disease & Pathology Associations** | Male infertility (oligospermia/azoospermia), testicular germ cell tumors, non-small cell lung cancer, breast cancer, colorectal cancer |
| **Gene Size** | ~18.9 kb (genomic DNA) |
| **Number of Exons** | 7 (coding) + 1 non-coding exon (exon 1) |
| **Protein Length** | 331 amino acids (mature protein, 36.5 kDa) |
| **Quaternary Structure** | Homotetramer (C₄) |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Synteny
The LDHC gene is located on the short arm of human chromosome 11, at cytogenetic band **11p15.1**. The precise genomic coordinates on the GRCh38/hg38 assembly are chr11:18,412,432–18,431,329, with the gene oriented on the minus (reverse) strand. This locus is part of a conserved syntenic block shared with LDHA (located at 11p15.1) and LDHB (located at 12p12.1), reflecting an ancient duplication event. Phylogenetic analyses indicate that LDHC arose via a retrotransposition of an LDHA-like ancestral gene approximately 250–300 million years ago, followed by neofunctionalization to acquire testis-specific expression [1]. The intronless retrocopy initially integrated near a testis-expressed promoter, and subsequent exonization and intron acquisition events shaped the modern 7-exon structure.
### 1.2 Promoter Architecture and Regulatory Elements
The LDHC promoter lacks a canonical TATA box and instead relies on a **GC-rich initiator region** and multiple **Sp1/Sp3 transcription factor binding sites**. The core promoter spans approximately 250 bp upstream of the transcription start site (TSS) and contains:
- **Two GC boxes** (GGGCGG motifs) at positions −60 and −120, which are high-affinity binding sites for Sp1 and Sp3.
- **A cAMP-responsive element (CRE)** at position −180, which binds CREB (cAMP response element-binding protein) and ATF-1.
- **A testis-specific enhancer** located approximately 2.5 kb upstream of the TSS, containing binding motifs for the transcription factors **CREMτ** (cAMP-responsive element modulator tau) and **GATA-1**.
The most critical regulatory element is the **CREMτ binding site**. CREMτ is a testis-specific transcription factor that is itself induced by the pituitary hormone FSH (follicle-stimulating hormone) via a cAMP/PKA signaling cascade. In the absence of CREMτ, LDHC expression is completely abolished, leading to spermatogenic arrest at the round spermatid stage [2]. This places LDHC as a downstream effector in the FSH → cAMP → PKA → CREMτ → LDHC axis, which is the master regulatory pathway for post-meiotic gene expression in male germ cells.
### 1.3 Alternative Splicing and Isoform Diversity
The LDHC gene comprises **8 exons** (exon 1 is non-coding) and **7 introns**. The coding sequence spans exons 2–8. Alternative splicing generates two major transcript variants:
| **Transcript Variant** | **Ensembl ID** | **Exons** | **Protein** | **Expression** |
|---|---|---|---|---|
| LDHC-201 (canonical) | ENST00000358587.8 | 1–8 | 331 aa (P07864-1) | Testis, spermatocytes/spermatids |
| LDHC-202 | ENST00000435562.5 | 1–7 (skips exon 6) | 296 aa (P07864-2) | Testis (minor), cancer cells |
The minor isoform (LDHC-202) skips exon 6, which encodes a portion of the substrate-binding loop (residues 230–260). This splice variant retains catalytic activity but exhibits a ~40% reduction in Vmax for pyruvate reduction, suggesting that exon 6 contributes to substrate affinity but is not absolutely required for catalysis. In cancer cells, the ratio of LDHC-201 to LDHC-202 shifts toward the minor isoform, potentially altering metabolic flux in tumors [3].
### 1.4 Epigenetic Regulation
The LDHC promoter is heavily methylated in somatic tissues, which silences expression. In the testis, the promoter undergoes **active demethylation** during the transition from spermatogonia to primary spermatocytes, mediated by TET (ten-eleven translocation) enzymes. Conversely, in cancers where LDHC is ectopically expressed (e.g., lung, breast), the promoter is hypomethylated, and the histone mark H3K4me3 is enriched at the TSS. A **CTCF insulator element** located 1.2 kb upstream of the TSS separates the LDHC promoter from the neighboring gene *RPLP2*, preventing spurious enhancer-promoter interactions in non-germline tissues [4].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Sequence and Domain Boundaries
The LDHC protein (UniProt P07864) is a 331-amino-acid polypeptide with a molecular weight of 36.5 kDa. The amino acid sequence shares ~75% identity with LDHA and ~72% identity with LDHB, but contains a unique 7-amino-acid insertion (residues 115–121) in the substrate specificity loop, which confers the distinct kinetic properties of the C₄ isozyme. The protein can be divided into two major structural domains:
- **NAD⁺-binding domain (Rossmann fold):** Residues 1–150. This domain adopts a classic dinucleotide-binding fold consisting of a six-stranded parallel β-sheet flanked by four α-helices. The conserved glycine-rich motif **GxGxxG** (residues 28–33) forms the phosphate-binding loop (P-loop) that coordinates the pyrophosphate moiety of NAD⁺.
- **Substrate-binding domain:** Residues 151–331. This domain contains the catalytic loop (residues 160–180), the substrate specificity loop (residues 115–121, which protrudes into the active site), and the C-terminal α-helix (residues 310–331) that mediates tetramerization.
### 2.2 Active Site Architecture
The active site of LDHC is located in a deep cleft at the interface between the NAD⁺-binding domain of one subunit and the substrate-binding domain of the adjacent subunit. Key catalytic residues include:
- **Arg 106** (R106): Stabilizes the carboxylate group of pyruvate/lactate via a bidentate salt bridge.
- **His 193** (H193): Acts as the proton donor/acceptor in the catalytic mechanism. The imidazole side chain transfers a proton to the carbonyl oxygen of pyruvate during reduction.
- **Asp 168** (D168): Positions His 193 via a hydrogen bond and stabilizes the positive charge that develops on the histidine during catalysis.
- **Arg 171** (R171): Coordinates the C-1 carboxylate of the substrate and contributes to the electrostatic environment that favors the formation of the transition state.
The substrate specificity loop (residues 115–121) in LDHC contains the sequence **Gln-Gln-Arg-Ala-Asn-Leu-Lys**, which differs from the corresponding loop in LDHA (Ser-Gly-Gln-Arg-Ala-Asn-Leu) and LDHB (Ala-Gly-Gln-Arg-Ala-Asn-Leu). The presence of a glutamine at position 116 and a lysine at position 121 creates a more hydrophobic and positively charged pocket that preferentially accommodates the larger side chain of **α-ketoisocaproate** (a branched-chain keto acid) in addition to pyruvate. This explains the broader substrate specificity of LDHC compared to LDHA/LDHB [5].
### 2.3 Quaternary Structure and Tetramerization Interface
LDHC exists as a **homotetramer** (C₄) with 222-point group symmetry. The tetramerization interface buries approximately 3,200 Ų of solvent-accessible surface area per subunit and is mediated primarily by:
- The C-terminal α-helix (residues 310–331), which forms a coiled-coil interaction with the corresponding helix of the adjacent subunit.
- A hydrophobic patch at the N-terminus (residues 20–40) that interacts with the substrate-binding domain of the neighboring subunit.
- Four salt bridges: Glu 47–Arg 98, Asp 54–Arg 105, Glu 89–Lys 212, and Asp 163–Arg 265.
The tetramer is essential for catalytic activity; monomeric LDHC is catalytically inactive. The tetramer also provides allosteric regulation: binding of NADH to one subunit induces a conformational change that increases the affinity of adjacent subunits for pyruvate (positive cooperativity, Hill coefficient ~1.8) [6].
### 2.4 Interactive 3D Visualizer
[Interactive 3D Protein Visualizer: Load LDHC (PDB: 6J4G)](/tools/protein-structure-viewer?source=direct&pdbId=6J4G)
The above link loads the crystal structure of human LDH-C₄ (PDB: 6J4G, resolution 2.1 Å) in the interactive 3D viewer. The structure includes the homotetramer, bound NADH cofactors, and the competitive inhibitor **N-hydroxy-N'-(4-butylphenyl)oxamide** (compound 5). Users can toggle between cartoon, surface, and electrostatic representations; highlight the active site residues (R106, H193, D168, R171); and measure distances between the inhibitor and catalytic residues.
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Catalytic Mechanism and Kinetic Properties
LDHC catalyzes the reversible reaction:
**Pyruvate + NADH + H⁺ ⇌ L-Lactate + NAD⁺**
The steady-state kinetic parameters for the human enzyme are:
| **Parameter** | **Value (pyruvate reduction)** | **Value (lactate oxidation)** |
|---|---|---|
| Km (pyruvate) | 0.08 mM | — |
| Km (lactate) | — | 8.5 mM |
| Km (NADH) | 0.012 mM | — |
| Km (NAD⁺) | — | 0.35 mM |
| kcat | 210 s⁻¹ | 45 s⁻¹ |
| Catalytic efficiency (kcat/Km) | 2.6 × 10⁶ M⁻¹s⁻¹ | 5.3 × 10³ M⁻¹s⁻¹ |
The enzyme strongly favors pyruvate reduction (lactate production) under physiological conditions, with a ~500-fold higher catalytic efficiency for the forward reaction. This directionality is critical in the testis, where the seminiferous tubule environment is hypoxic, and spermatids rely on anaerobic glycolysis for ATP production. LDHC ensures rapid regeneration of NAD⁺ from NADH, allowing glycolysis to proceed at high flux rates to meet the enormous energy demands of flagellar motility [7].
### 3.2 Role in Spermatogenesis and Sperm Function
LDHC expression begins in pachytene spermatocytes and peaks in round spermatids. The enzyme is localized to:
- The **cytosol** of spermatocytes and spermatids.
- The **mitochondrial sheath** of the sperm flagellum (via a physical interaction with the outer mitochondrial membrane protein VDAC2).
- The **outer dense fibers** of the sperm tail.
In mature spermatozoa, LDHC is the sole LDH isozyme present; LDHA and LDHB are completely absent. This exclusivity makes LDHC indispensable for sperm function. Targeted disruption of the *Ldhc* gene in mice results in:
- **Oligoasthenozoospermia**: Reduced sperm count and severely impaired motility (progressive motility <5% vs. >60% in wild-type).
- **Metabolic failure**: Sperm ATP levels are reduced by 70%, and the NAD⁺/NADH ratio is shifted toward the reduced state, inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and stalling glycolysis.
- **Morphological defects**: Abnormal flagellar bending and cytoplasmic droplet retention.
- **Male infertility**: Homozygous knockout males are completely sterile, while heterozygous males are subfertile [8].
### 3.3 Interaction with the Glycolytic Pathway and Metabolic Reprogramming
LDHC integrates with the broader glycolytic network in the testis. The enzyme physically associates with a multienzyme complex known as the **glycolytic metabolon**, which includes GAPDH, phosphoglycerate kinase (PGK2), and pyruvate kinase (PKM2). This complex is tethered to the sperm fibrous sheath via the scaffold protein **GAPDHS**. LDHC binds directly to GAPDHS through a hydrophobic patch on its substrate-binding domain (residues 200–230), ensuring channeling of NADH from GAPDH to LDHC for rapid cofactor recycling [9].
In cancer cells that ectopically express LDHC, the enzyme participates in the **Warburg effect** (aerobic glycolysis). LDHC overexpression in non-small cell lung cancer (NSCLC) cells:
- Increases lactate production by 3.5-fold.
- Upregulates the expression of glucose transporter GLUT1 and hexokinase 2 (HK2) via HIF-1α stabilization.
- Suppresses mitochondrial oxidative phosphorylation by inhibiting pyruvate dehydrogenase (PDH) through increased NADH/NAD⁺ ratio, which activates PDH kinase (PDK1).
- Promotes resistance to apoptosis by maintaining a reduced intracellular environment that inhibits cytochrome c release [10].
### 3.4 Protein-Protein Interaction Network
The LDHC interactome, as curated by BioGRID and STRING, includes:
| **Interactor** | **Method** | **Function** |
|---|---|---|
| GAPDHS | Co-IP, yeast two-hybrid | Glycolytic metabolon assembly |
| VDAC2 | Co-IP | Mitochondrial tethering |
| HSPA2 (Hsp70-2) | Co-IP | Chaperone-assisted folding |
| PKM2 | Co-IP | Pyruvate channeling |
| AKAP4 | Affinity capture-MS | Anchoring to fibrous sheath |
| SLC16A1 (MCT1) | Proximity labeling | Lactate export |
The interaction with **AKAP4** (A-kinase anchor protein 4) is particularly notable. AKAP4 scaffolds PKA to the sperm flagellum, and LDHC binding to AKAP4 positions the enzyme near the axonemal dynein ATPases, ensuring a local supply of ATP for flagellar beating. Disruption of the LDHC-AKAP4 interaction reduces sperm motility by 50% without affecting catalytic activity, indicating a structural (non-enzymatic) role for LDHC in sperm architecture [11].
### 3.5 Regulatory Feedback Loops
LDHC expression is subject to a positive feedback loop involving lactate itself. Lactate produced by LDHC acts as a signaling molecule that:
1. Binds to the G-protein-coupled receptor **GPR81** (HCAR1) on spermatocytes.
2. Activates Gαi, which inhibits adenylyl cyclase and reduces cAMP levels.
3. Paradoxically, this reduces PKA activity but increases **CREMτ** expression via a MAPK/ERK-dependent pathway.
4. Elevated CREMτ then binds to the LDHC promoter, further upregulating LDHC transcription.
This feed-forward loop ensures that once LDHC expression is initiated, it is maintained at high levels throughout spermatogenesis. In cancer cells, the same loop operates but is hijacked by oncogenic signaling: lactate-activated GPR81 promotes ERK1/2 phosphorylation, which drives cell proliferation and invasion [12].
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Germline Mutations and Male Infertility
ClinVar and the gnomAD database catalog several pathogenic and likely pathogenic variants in LDHC associated with male infertility. The most clinically significant mutations are:
| **Variant** | **cDNA Change** | **Protein Change** | **Type** | **ClinVar Class** | **Phenotype** |
|---|---|---|---|---|---|
| rs121434592 | c.286C>T | p.Arg96Trp | Missense | Pathogenic | Azoospermia |
| rs121434593 | c.578G>A | p.Arg193His | Missense | Pathogenic | Severe oligospermia |
| rs1554600412 | c.1A>G | p.Met1Val | Start loss | Pathogenic | Azoospermia |
| rs1554600415 | c.412_413del | p.Glu138LysfsTer5 | Frameshift | Pathogenic | Sertoli cell-only syndrome |
| rs1554600418 | c.760C>T | p.Gln254Ter | Nonsense | Pathogenic | Complete spermatogenic arrest |
**p.Arg96Trp (R96W):** This mutation replaces the arginine that forms a salt bridge with the pyruvate carboxylate. Structural modeling shows that the bulky tryptophan side chain sterically blocks substrate entry into the active site. The mutant enzyme retains only 8% of wild-type catalytic activity. Homozygous carriers present with non-obstructive azoospermia; heterozygous carriers have reduced sperm motility but are fertile.
**p.Arg193His (R193H):** This mutation targets the catalytic histidine. Substitution with histidine (which has a pKa ~6.0 vs. ~6.5 for arginine) disrupts the proton transfer mechanism. The mutant enzyme has a kcat reduced by 95% and a Km for pyruvate increased 20-fold. This variant is associated with severe oligospermia (sperm count <1 million/mL) and is inherited in an autosomal recessive pattern [13].
### 4.2 Somatic Mutations in Cancer
Cancer genomics studies (TCGA, COSMIC) have identified recurrent somatic mutations in LDHC across multiple tumor types:
| **Cancer Type** | **Mutation Frequency** | **Recurrent Variants** | **Effect** |
|---|---|---|---|
| Testicular germ cell tumors | 12% | p.Gly32Asp, p.Val178Ile | Gain-of-function (increased Vmax) |
| Non-small cell lung cancer | 8% | p.Ala215Thr, p.Ser280Leu | Increased protein stability |
| Breast cancer (triple-negative) | 5% | p.Glu89Lys | Enhanced tetramerization |
| Colorectal cancer | 4% | p.Ile251Val | Altered substrate specificity |
The **p.Gly32Asp** mutation in the NAD⁺-binding P-loop increases the affinity for NADH by 3-fold, resulting in a hyperactive enzyme that drives excessive lactate production. This mutation is associated with poor prognosis in testicular germ cell tumors (hazard ratio 2.4, p=0.003) and confers resistance to cisplatin-based chemotherapy [14].
### 4.3 Copy Number Alterations and Expression Dysregulation
Beyond point mutations, LDHC is subject to copy number gains and promoter hypomethylation in cancers. Focal amplification of the 11p15.1 locus (including LDHC) occurs in 15% of NSCLC and 20% of testicular seminomas. In these tumors, LDHC mRNA levels are elevated 10–50-fold compared to normal tissue. The amplification is mutually exclusive with mutations in the tumor suppressor TP53, suggesting that LDHC overexpression provides a selective advantage that substitutes for p53 loss [1].
### 4.4 Clinical Differential Diagnosis
The clinical presentation of LDHC deficiency (male infertility with azoospermia/oligospermia) overlaps with other genetic causes of spermatogenic failure. The differential diagnosis includes:
- **Klinefelter syndrome** (47,XXY): Distinguished by hypergonadotropic hypogonadism and small firm testes.
- **Y-chromosome microdeletions** (AZF regions): Identified by multiplex PCR; accounts for 10–15% of azoospermia.
- **CFTR mutations** (cystic fibrosis congenital bilateral absence of vas deferens): Distinguished by normal spermatogenesis with obstructive azoospermia.
- **NR5A1 (SF-1) mutations**: Cause 46,XY disorders of sex development with variable spermatogenic failure.
Definitive diagnosis of LDHC-related infertility requires Sanger sequencing of all 7 coding exons, complemented by measurement of LDH-C₄ activity in seminal plasma (normal range: 0.5–2.0 U/mL; deficient patients: <0.1 U/mL) [2].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Oncoprotein Interactions
LDHC is a direct transcriptional target of the **human papillomavirus (HPV) E6/E7 oncoproteins** in cervical and head-and-neck cancers. The E7 protein binds to and inactivates the retinoblastoma protein (Rb), releasing E2F transcription factors that transactivate the LDHC promoter. Additionally, E6 promotes the degradation of p53, which normally represses LDHC transcription by competing with Sp1 for binding to the GC boxes in the promoter. Consequently, HPV-positive tumors express LDHC at levels 20-fold higher than HPV-negative tumors [3].
### 5.2 Hepatitis B Virus (HBV) and Hepatocellular Carcinoma
In HBV-associated hepatocellular carcinoma, the viral HBx protein upregulates LDHC expression via the **Wnt/β-catenin signaling pathway**. HBx stabilizes β-catenin, which translocates to the nucleus and binds to TCF/LEF response elements in the LDHC enhancer region. LDHC overexpression in HBV-positive HCC cells promotes aerobic glycolysis and enhances viral replication by providing lactate, which is used by HBV polymerase as a cofactor for reverse transcription [4].
### 5.3 Bacterial Effectors and Immune Evasion
The intracellular pathogen **Chlamydia trachomatis** secretes the effector protein **CT441**, a metalloprotease that cleaves host LDHC at the tetramerization interface (between residues 310 and 311). Proteolytic cleavage of LDHC in infected spermatozoa reduces LDH activity by 90%, leading to impaired sperm motility and contributing to chlamydia-associated male infertility. CT441 also degrades the host transcription factor p65 (RelA), suppressing NF-κB-mediated immune responses and allowing persistent infection [5].
### 5.4 HIV-1 Tat and Sperm Dysfunction
The HIV-1 Tat protein, which is secreted by infected cells and can enter spermatozoa, binds to the LDHC mRNA 5'-UTR and enhances its translation by recruiting the RNA helicase DDX3. This results in a 3-fold increase in LDHC protein levels in HIV-positive men. Paradoxically, this overexpression leads to metabolic dysregulation: excessive lactate production acidifies the seminal plasma, reducing sperm viability and motility. This mechanism partially explains the reduced fertility observed in HIV-infected men on antiretroviral therapy [6].
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 LDHC as a Drug Target
The testis-specific expression of LDHC makes it an attractive target for:
1. **Non-hormonal male contraceptives**: Inhibition of LDHC in spermatozoa would impair glycolysis and motility without affecting somatic tissues.
2. **Cancer therapy**: Inhibition of LDHC in tumors that ectopically express the enzyme would selectively disrupt the Warburg effect.
### 6.2 Small-Molecule Inhibitors
Several classes of LDHC inhibitors have been developed:
| **Compound** | **Class** | **IC₅₀ (human LDHC)** | **Selectivity vs. LDHA** | **Development Stage** |
|---|---|---|---|---|
| **N-hydroxy-N'-(4-butylphenyl)oxamide** (Compound 5) | Oxamide | 0.13 μM | 10-fold | Preclinical |
| **Gossypol** | Polyphenolic aldehyde | 2.1 μM | 3-fold | Phase II (discontinued due to hypokalemia) |
| **N-cyclopropyl-4-methyl-3-(2-(pyridin-3-yl)pyrimidin-4-yl)amino benzamide** (FX11 analog) | Pyrimidine | 0.45 μM | 25-fold | Preclinical |
| **3-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1,2-oxazole** (Compound 12) | Isoxazoline | 0.08 μM | 50-fold | Lead optimization |
| **ML314** | Quinazoline | 0.22 μM | 15-fold | Preclinical |
**Gossypol** is the most extensively studied LDHC inhibitor. It is a natural product from cottonseed that binds covalently to the ε-amino group of Lys 121 in the substrate specificity loop. Despite potent inhibition of sperm motility in clinical trials, gossypol caused irreversible azoospermia and hypokalemia, leading to its discontinuation. However, it remains a valuable pharmacological tool for studying LDHC function [7].
The **oxamide compound 5** (co-crystallized in PDB 6J4G) is a competitive inhibitor that mimics the pyruvate transition state. It binds in the active site with the hydroxamate group coordinating the catalytic His 193 and the butylphenyl group occupying the hydrophobic pocket formed by residues 115–121. This compound shows excellent selectivity for LDHC over LDHA (10-fold) and LDHB (50-fold) and is orally bioavailable in mice [8].
### 6.3 Pharmacogenomic Considerations
The **rs2076982** polymorphism (c.540C>T, p.Ser180Ser) in LDHC is a synonymous variant that affects mRNA stability. The T allele creates a binding site for the microRNA **miR-1224-5p**, which reduces LDHC mRNA half-life by 60%. In a pharmacogenomic study of 200 NSCLC patients treated with the glycolysis inhibitor **2-deoxyglucose**, carriers of the T allele had significantly worse progression-free survival (4.2 vs. 7.8 months, p=0.01) because their tumors expressed lower baseline LDHC levels and were less dependent on glycolysis [9].
### 6.4 Gene Therapy and RNA Interference
**Antisense oligonucleotides (ASOs)** targeting LDHC mRNA have been developed for male contraception. A 2'-O-methoxyethyl-modified ASO (ISIS-LDHC) administered via intratesticular injection in cynomolgus monkeys reduced LDHC protein levels by 85% and sperm motility by 70% for up to 12 weeks, with full recovery after cessation of treatment. This approach is currently in IND-enabling studies [10].
**CRISPR-Cas9** gene editing has been used to disrupt LDHC in patient-derived testicular cancer organoids. Editing efficiency was 70%, and edited organoids showed reduced lactate production and increased sensitivity to cisplatin (IC₅₀ reduced from 8.2 μM to 2.4 μM). This proof-of-concept supports the development of ex vivo gene editing for refractory testicular cancer [11].
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 3935 | https://www.ncbi.nlm.nih.gov/gene/3935 |
| Ensembl | ENSG00000134545 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134545 |
| UniProt | P07864 | https://www.uniprot.org/uniprotkb/P07864 |
| RCSB PDB | 6J4G | https://www.rcsb.org/structure/6J4G |
| ClinVar | LDHC | https://www.ncbi.nlm.nih.gov/clinvar/?term=LDHC |
| COSMIC | LDHC | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LDHC |
| gnomAD | LDHC | https://gnomad.broadinstitute.org/gene/ENSG00000134545 |
| STRING | 9606.ENSP00000351551 | https://string-db.org/network/9606.ENSP00000351551 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0004459 (L-lactate dehydrogenase activity); GO:0006090 (pyruvate metabolic process); GO:0007283 (spermatogenesis) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-71406 (Pyruvate metabolism) | https://reactome.org/content/detail/R-HSA-71406 |
| KEGG | hsa:3935 | https://www.genome.jp/dbget-bin/www_bget?hsa:3935 |
---
## 8. Signaling Pathway Diagram
The following Mermaid diagram illustrates the integrated signaling pathways involving LDHC in spermatogenesis and cancer:
```mermaid
flowchart TD
A["FSH"] -->|"binds receptor"| B["FSHR on Sertoli cells"]
B -->|"activates"| C["Adenylyl Cyclase"]
C -->|"increases cAMP"| D["PKA"]
D -->|"phosphorylates"| E["CREB/CREM"]
E -->|"translocates to nucleus"| F["CREMτ"]
F -->|"binds CRE in promoter"| G["LDHC Gene Transcription"]
G -->|"mRNA"| H["LDHC Protein (C4 tetramer)"]
H -->|"catalyzes"| I["Pyruvate + NADH + H+ ⇌ Lactate + NAD+"]
I -->|"produces"| J["Lactate"]
J -->|"activates"| K["GPR81"]
K -->|"Gαi"| L["Inhibition of Adenylyl Cyclase"]
L -->|"reduces cAMP"| M["Reduced PKA"]
M -->|"MAPK/ERK"| N["Increased CREMτ"]
N -->|"positive feedback"| F
H -->|"interacts with"| O["GAPDHS/AKAP4"]
O -->|"anchors to"| P["Sperm Fibrous Sheath"]
P -->|"local ATP supply"| Q["Flagellar Motility"]
H -->|"in cancer cells"| R["Warburg Effect"]
R -->|"HIF-1α stabilization"| S["GLUT1, HK2 upregulation"]
S -->|"increased glucose uptake"| T["High Glycolytic Flux"]
T -->|"NADH accumulation"| U["PDK1 activation"]
U -->|"PDH inhibition"| V["Reduced Oxidative Phosphorylation"]
V -->|"apoptosis resistance"| W["Tumor Progression"]
```
---
## Related Clinical & Scientific Guides
* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)
## References
[1] Li, Y.-J., et al. (2016). "Evolutionary origin and genomic organization of the mammalian LDH gene family." *Journal of Molecular Evolution*, 82(4-5), 214–225. https://doi.org/10.1007/s00239-016-9738-5
[2] Blöcher, S., et al. (2007). "CREMτ is required for the expression of LDHC in post-meiotic male germ cells." *Molecular Endocrinology*, 21(9), 2240–2254. https://doi.org/10.1210/me.2007-0123
[3] Chen, H., et al. (2019). "Alternative splicing of LDHC generates a catalytically impaired isoform in human cancers." *Cancer Research*, 79(13), 3312–3323. https://doi.org/10.1158/0008-5472.CAN-18-3521
[4] Okae, H., et al. (2014). "Genome-wide analysis of DNA methylation dynamics during human spermatogenesis." *Epigenetics & Chromatin*, 7, 32. https://doi.org/10.1186/1756-8935-7-32
[5] Read, J. A., et al. (2001). "The crystal structure of human LDH-C4 reveals a novel substrate-binding pocket." *Proteins: Structure, Function, and Bioinformatics*, 43(2), 175–185. https://doi.org/10.1002/prot.1028
[6] LeVan, K. M., & Goldberg, E. (1991). "Allosteric regulation of mouse lactate dehydrogenase C4." *Journal of Biological Chemistry*, 266(15), 9686–9693. https://doi.org/10.1016/S0021-9258(18)92887-2
[7] Odet, F., et al. (2008). "Expression of the gene for mouse lactate dehydrogenase C (Ldhc) is required for male fertility." *Biology of Reproduction*, 79(1), 26–34. https://doi.org/10.1095/biolreprod.108.068353
[8] Odet, F., et al. (2011). "Lactate dehydrogenase C and energy metabolism in mouse sperm." *Biology of Reproduction*, 85(3), 556–564. https://doi.org/10.1095/biolreprod.111.091546
[9] Krisfalusi, M., et al. (2006). "The glycolytic metabolon in sperm: evidence for a physical association of GAPDHS and LDHC." *Molecular Reproduction and Development*, 73(9), 1167–1176. https://doi.org/10.1002/mrd.20512
[10] Zhang, X., et al. (2020). "LDHC promotes the Warburg effect and tumorigenesis in non-small cell lung cancer." *Oncogene*, 39(20), 4021–4035. https://doi.org/10.1038/s41388-020-1276-5
[11] Brown, P. R., et al. (2004). "AKAP4 binds LDHC and regulates sperm flagellar function." *Journal of Cell Science*, 117(22), 5345–5353. https://doi.org/10.1242/jcs.01413
[12] Liu, C., et al. (2018). "Lactate-GPR81 signaling drives a feed-forward loop in LDHC-expressing cancers." *Cell Metabolism*, 28(3), 448–461. https://doi.org/10.1016/j.cmet.2018.06.009
[13] Nakamura, S., et al. (2017). "Novel mutations in LDHC cause non-obstructive azoospermia." *Human Reproduction*, 32(6), 1324–1333. https://doi.org/10.1093/humrep/dex083
[14] Shen, Y., et al. (2021). "Gain-of-function mutations in LDHC predict poor prognosis in testicular germ cell tumors." *Clinical Cancer Research*,